Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
ClinicalTrials.gov Identifier:
NCT01795677
First received: December 21, 2012
Last updated: June 24, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)